Mazdutide positive Phase III results to help Innovent gain widespread adoption in China obesity market
China-based Innovent Biologics (HKEX: 01801) recently made a significant breakthrough in obesity treatment with mazdutide, showcasing promising Phase III (GLORY-1) results.
Poised to enter the Chinese market, mazdutide heralds a new era in obesity management, reflecting the China-based biotech company’s commitment to innovative healthcare solutions and addressing the growing need for effective obesity treatments in one of the world's largest patient populations, says pharma analytics firm GlobalData.
Mazdutide is Eli Lilly’s (NYSE: LLY) next-generation obesity asset that Innovent is developing as part of a 2019 deal with the US pharma major where it secured the rights to the dual glucagon-like peptide-1 (GLP-1)/glucagon receptor agonist.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze